CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

@article{Zeltsman2017CARTT,
  title={CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.},
  author={Masha Zeltsman and Jordan Dozier and Erin McGee and Daniel Chi Kit Ngai and Prasad S Adusumilli},
  journal={Translational research : the journal of laboratory and clinical medicine},
  year={2017},
  volume={187},
  pages={
          1-10
        }
}
Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. One… CONTINUE READING
BETA
3
Twitter Mentions

Similar Papers

Loading similar papers…